We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

HemaTrate™ in the Treatment of Critical Limb Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03809494
Recruitment Status : Terminated (The study has stopped early due to enrollment challenges related largely to the current pandemic)
First Posted : January 18, 2019
Last Update Posted : December 2, 2020
Information provided by (Responsible Party):
Cook Group Incorporated ( Cook Research Incorporated )

Brief Summary:
The primary objective of this study is to evaluate the performance of the HemaTrate™ Blood Filtration system in the treatment of critical limb ischemia. The primary endpoint measure is comparing the percentage of patients between the treatment arm and control arm who have freedom from major amputation, arterial intervention below the knee, and death through 12 months.

Condition or disease Intervention/treatment Phase
Critical Limb Ischemia Ischemia Device: HemaTrate™ Blood Filtration system Other: Saline Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: The investigator for this study is the person that will be performing the injections throughout the study and will know the participant's treatment (TNC or saline). The investigator that is aware of the participant's treatment will not be performing the follow-up visits.
Primary Purpose: Treatment
Official Title: Clinical Study of the Use of an Autologous Blood Filtration Device in the Treatment of Critical Limb Ischemia
Actual Study Start Date : July 23, 2019
Actual Primary Completion Date : November 27, 2020
Actual Study Completion Date : November 27, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment Arm
Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
Device: HemaTrate™ Blood Filtration system
Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.

Placebo Comparator: Saline (Control Arm)
Patients assigned to the control arm will be injected with saline three times at six week intervals.
Other: Saline
Normal (0.9%) saline

Primary Outcome Measures :
  1. Freedom from vascular or endovascular arterial intervention below the knee of the study leg [ Time Frame: 12 months ]
    Percent of patients that have vascular or endovascular arterial intervention reported below the knee of the study leg

  2. Freedom from major amputation of the study leg [ Time Frame: 12 months ]
    Percent of patients that have any amputation above the ankle of the study leg

  3. Death [ Time Frame: 12 months ]
    Percent of patients that exit due to death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Critical Limb Ischemia in the study leg with ischemic rest pain and/or ulcer/minor tissue loss (Rutherford 4 or 5)
  2. Previously failed an endovascular or surgical treatment of the study lower leg and is not being considered for additional intervention within the next 3 months OR is unsuitable for revascularization

Exclusion Criteria:

  1. Simultaneously participating in another investigational study (e.g., drug or device)
  2. Pregnant or breastfeeding, or planning to become pregnant within the next 12 months
  3. Major surgery (open cardiac, vascular, or abdominal procedure) within the past 90 days
  4. Endovascular intervention within the past 30 days
  5. Current dialysis, or expected to need dialysis within the next 12 months
  6. Previous above the ankle amputation in the study leg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03809494

Layout table for location information
United Kingdom
Manchester Royal Infirmary, Manchester Vascular Centre
Manchester, Great Britian, United Kingdom, M13 9WL
The Leeds Teaching Hospital NHS Trust
Leeds, West Yorkshire, United Kingdom, LS9 7TF
St Thomas' Hospital
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
Cook Research Incorporated
Layout table for investigator information
Study Chair: Bijan Modarai, PhD, FRCS St Thomas' Hospital
Study Chair: Václav Procházka, MD, PhD, MSc University Hospital Ostrava
Study Chair: Giulio Pompilio, MD, PhD Centro Cardiologico Monzino IRCCS
Layout table for additonal information
Responsible Party: Cook Research Incorporated
ClinicalTrials.gov Identifier: NCT03809494    
Other Study ID Numbers: 15-03
First Posted: January 18, 2019    Key Record Dates
Last Update Posted: December 2, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request after publication of the results from this study and ending 5 years after initial publication. Interested researchers may review the "Cook Research Incorporated Policy on Access to Clinical Study Data" at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cook Group Incorporated ( Cook Research Incorporated ):
lower extremity
Peripheral Arterial Disease
Peripheral Blood Stem Cell Transplantation
Leukocytes, Mononuclear
Transplantation, Autologous
Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Limb-Threatening Ischemia
Pathologic Processes
Peripheral Arterial Disease
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Chronic Disease
Disease Attributes